NEW YORK (GenomeWeb) – Goldman Sachs on Wednesday downgraded shares of Qiagen and Bruker to a Sell rating.

The investment bank also lowered its six-month price target for Qiagen to $19 from a prior target of $21 and the 12-month price target for Bruker to $15 from $21.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.